Healthcare provider profile · identity verified

Karim R. Harfouche, MD

Allopathic & Osteopathic Physicians|Internal Medicine · MARGATE, FL · NPI 1003046897

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Karim R. Harfouche, MD received $13.55 in general payments during 2025 across 1 reported records.

Amgen Inc. accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$13.55

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Amgen Inc.	Unresolved — no canonical attribution shown	$13.55	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$13.55	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
OTEZLA Normalized: otezla	Drug	Amgen Inc.	$13.55	1	2025
Source payment records 2025-08-08 · Amgen Inc. · $13.55 · Open Payments source
REPATHA Normalized: repatha	Biological	Amgen Inc.	$13.55	1	2025
Source payment records 2025-08-08 · Amgen Inc. · $13.55 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	674	228
Amlodipine Besylate	Amlodipine Besylate	455	137
Losartan Potassium	Losartan Potassium	393	121
Metformin Hcl	Metformin Hcl	296	101
Rosuvastatin Calcium	Rosuvastatin Calcium	287	95
Levothyroxine Sodium	Levothyroxine Sodium	225	67
Lisinopril	Lisinopril	218	68
Gabapentin	Gabapentin	184	77
Ezetimibe	Ezetimibe	172	60
Famotidine	Famotidine	162	59
Tamsulosin Hcl	Tamsulosin Hcl	161	52
Metoprolol Succinate	Metoprolol Succinate	138	52
Carvedilol	Carvedilol	132	40
Nifedipine Er	Nifedipine	132	36
Hydrochlorothiazide	Hydrochlorothiazide	131	49
Ibuprofen	Ibuprofen	125	45
Meloxicam	Meloxicam	120	55
Omeprazole	Omeprazole	120	49
Albuterol Sulfate Hfa	Albuterol Sulfate	114	33
Glipizide	Glipizide	110	39
Pantoprazole Sodium	Pantoprazole Sodium	107	40
Alendronate Sodium	Alendronate Sodium	102	31
Sertraline Hcl	Sertraline Hcl	101	37
Clopidogrel	Clopidogrel Bisulfate	91	26
Metformin Hcl Er	Metformin Hcl	91	27
Memantine Hcl	Memantine Hcl	85	34
Metoprolol Tartrate	Metoprolol Tartrate	84	26
Meclizine Hcl	Meclizine Hcl	83	37
Januvia	Sitagliptin Phosphate	82	22
Azithromycin	Azithromycin	76	55
Simvastatin	Simvastatin	76	22
Trulicity	Dulaglutide	70	suppressed
Jardiance	Empagliflozin	68	18
Montelukast Sodium	Montelukast Sodium	66	25
Hydralazine Hcl	Hydralazine Hcl	65	23
Linzess	Linaclotide	61	19
Furosemide	Furosemide	60	24
Ketoconazole	Ketoconazole	57	20
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	55	18
Quetiapine Fumarate	Quetiapine Fumarate	51	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	48	17
Latanoprost	Latanoprost	47	16
Baclofen	Baclofen	46	15
Clonazepam	Clonazepam	45	19
Eliquis	Apixaban	45	14
Finasteride	Finasteride	45	12
Donepezil Hcl	Donepezil Hcl	43	12
Glimepiride	Glimepiride	43	suppressed
Sucralfate	Sucralfate	43	14
Temazepam	Temazepam	43	suppressed
Symbicort	Budesonide/Formoterol Fumarate	42	13
Alprazolam	Alprazolam	41	14
Ciprofloxacin Hcl	Ciprofloxacin Hcl	41	28
Escitalopram Oxalate	Escitalopram Oxalate	40	suppressed
Xarelto	Rivaroxaban	40	suppressed
Allopurinol	Allopurinol	39	13
Sildenafil Citrate	Sildenafil Citrate	39	13
Esomeprazole Magnesium	Esomeprazole Magnesium	38	suppressed
Trazodone Hcl	Trazodone Hcl	38	11
Fenofibrate	Fenofibrate Nanocrystallized	36	11
Fluticasone Propionate	Fluticasone Propionate	35	13
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	32	25
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	32	19
Atenolol	Atenolol	31	suppressed
Farxiga	Dapagliflozin Propanediol	31	suppressed
Diclofenac Sodium	Diclofenac Sodium	30	11
Enalapril Maleate	Enalapril Maleate	29	suppressed
Pregabalin	Pregabalin	29	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	28	21
Mometasone Furoate	Mometasone Furoate	28	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	28	20
Doxycycline Hyclate	Doxycycline Hyclate	27	24
Lactulose	Lactulose	27	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	26	suppressed
Ozempic	Semaglutide	26	suppressed
Breyna	Budesonide/Formoterol Fumarate	25	suppressed
Tadalafil	Tadalafil	25	suppressed
Clotrimazole	Clotrimazole	24	suppressed
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	24	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	24	suppressed
Potassium Chloride	Potassium Chloride	24	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	23	suppressed
Benztropine Mesylate	Benztropine Mesylate	22	suppressed
Lorazepam	Lorazepam	22	suppressed
Clonidine Hcl	Clonidine Hcl	21	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	20	suppressed
Amiodarone Hcl	Amiodarone Hcl	19	suppressed
Entresto	Sacubitril/Valsartan	19	suppressed
Myrbetriq	Mirabegron	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	17	suppressed
Humulin R U-500 Kwikpen	Insulin Regular, Human	17	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	17	suppressed
Valsartan	Valsartan	17	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	16	suppressed
Nystatin	Nystatin	16	suppressed
Tizanidine Hcl	Tizanidine Hcl	16	suppressed
Torsemide	Torsemide	16	suppressed
Valacyclovir	Valacyclovir Hcl	16	suppressed
Warfarin Sodium	Warfarin Sodium	16	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	15	suppressed
Cefuroxime	Cefuroxime Axetil	15	14
Chlorthalidone	Chlorthalidone	15	suppressed
Clobetasol Propionate	Clobetasol Propionate	15	suppressed
Glipizide Er	Glipizide	15	suppressed
Metronidazole	Metronidazole	15	15
Neomycin-Polymyxin-Hydrocort	Neomycin/Polymyxin B/Hydrocort	15	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	15	suppressed
Novolin R Flexpen	Insulin Regular, Human	15	suppressed
Timolol Maleate	Timolol Maleate	15	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	14	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	14	suppressed
Ibandronate Sodium	Ibandronate Sodium	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Novolog Flexpen	Insulin Aspart	13	suppressed
Aripiprazole	Aripiprazole	12	suppressed
Genvoya	Elviteg/Cob/Emtri/Tenof Alafen	12	suppressed
Humalog Kwikpen U-100	Insulin Lispro	12	suppressed
Leflunomide	Leflunomide	12	suppressed
Methylprednisolone	Methylprednisolone	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	12	12
Prazosin Hcl	Prazosin Hcl	12	suppressed
Topiramate	Topiramate	12	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	11	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	11	suppressed
Betamethasone Valerate	Betamethasone Valerate	11	suppressed
Folic Acid	Folic Acid	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	11	suppressed
Naproxen	Naproxen	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed
Prednisone	Prednisone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$13.55 · 1 records	Amgen Inc.	OTEZLA, REPATHA	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error